TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00469651

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSP3 candidate vaccine
Description: Lyophilized MSP3 adjuvanted in Aluminium hydroxide

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B control vaccine
Description: Hepatitis B vaccine adjuvanted in Aluminium Hydroxide
Study: NCT00619593

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensified diagnostic and treatment measures following 1st appropriate ICD therapy
Description: * Assessment of general health status (weight, BP, NYHA)~* Laboratory tests (hemoglobin, Nt-proBNP, creatinine, GDF-15)~* Echocardiography (LVEF, LVEDD, mitral regurgitation)~* Non-invasive ischemia evaluation~* Coronary angiography (if indicated by ischemia evaluation)~* Upgrade to CRT, if indicated~* Ventricular ablation (if indicated: VT storm, slow VT, bundle branch reentry)~* 24 hrs ECG Holter (Heart rate variability)~* Further treatment (if applicable)~* Changes in ICD settings, or medication

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard follow-up
Description: Standard follow-up in patients without appropriate ICD therapy
Study: NCT02145585

Intervention type: DEVICE
Intervention: Test of pharmacologic anesthesia robot (labVIEW® software)
Study: NCT01007019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 100mg (repeat dose)
Description: YH4808 100mg (repeat dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 200mg (repeat dose)
Description: YH4808 200mg (repeat dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 600mg
Description: YH4808 600mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 800mg (single dose)
Description: YH4808 800mg (single dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 400 mg (repeat doses)
Description: YH4808 400 mg (repeat doses)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 volunteers will be administered matched placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40mg
Description: 24 volunteers will be administered Esomeprazole 40mg
Study: NCT02299687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Study: NCT03264664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7386
Description: Oral immediate release tablets.
Study: NCT03712202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Given IV
Study: NCT01783054

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Subjects will then receive surgery at MUSC within 4-8 weeks following completion of chemotherapy

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic Expression
Description: Subjects will have genetic expression testing done on their tissue samples.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Patients will receive gemcitabine at 1000 mg/m2 and abraxane at 125 mg/m2 intravenously on days 1, 8 and 15 of a 28 day cycle for 2 cycles
Study: NCT02457546

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EVICEL Fibrin Sealant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hydrogel sealant
Study: NCT01881958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DiaPep277®
Study: NCT02473302

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ham
Description: 160g per day during 4 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ham + pomegranate extract
Description: 160g per day during 4 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ham + tocopherol
Description: 160g per day during 4 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: rare sirloin steak
Description: 110g per day during 4 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: marinated rare sirloin steak
Description: 110g per day during 4 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: marinated cooked sirloin steak
Description: 110g per day during 4 days
Study: NCT03348462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethosomal preparation of anthralin
Description: once daily with short contact topical application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liposomal preparation of anthralin
Description: once daily with short contact topical application
Study: NCT01945112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paper Tape
Description: Applied to blister prone areas of the foot
Study: NCT02056145

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: LFCNB
Description: LFCNB - Normal Saline solution 10 cc

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LFCNB
Description: LFCNB - Normal Saline solution 10 cc

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: FNB
Description: FNB - Normal saline solution 10 cc

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LFCNB
Description: LFCNB - Chirocaine 0.25%, 20 cc

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FNB
Description: FNB - Chirocaine 0.25%, 20 cc
Study: NCT03757338

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fingolimod Reference Formulation
Description: To compare the rate and extent of absorption for Fingolimod when administered as a single oral dose of 3 x 0.5 mg capsules of the reference product produced by Novartis Pharmaceutical with the proposed test product manufactured by Asofarma S.A.I. y C. in healthy volunteers, under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod Test Formulation
Description: To compare the rate and extent of absorption for Fingolimod when administered as a single oral dose of 3 x 0.5 mg capsules of the proposed test product manufactured by Asofarma S.A.I. y C. with the reference product produced by Novartis Pharmaceutical in healthy volunteers, under fasted conditions.
Study: NCT02670434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NK-104-CR
Description: NK-104-CR 8 mg daily for 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Livalo
Description: Livalo® IR daily from week 12 to week 52
Study: NCT05843955

Intervention type: OTHER
Intervention: Questionnaire
Description: Nutritional status, physical activity levels, anthropometric measurements, and biochemical parameters of individuals were examined. A food consumption frequency questionnaire was administered.
Study: NCT03267251

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vacteens Web app for mobile devices
Description: The Web app provides parents of young adolescent girls (ages 11-14) accurate information about HPV Vaccination, and a number of tools to aid informed decision making.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Usual and Customary HPV Information - CDC pamphlet
Description: The usual communication about HPV Vaccination in clinics is for parents to be issued the CDC pamphlet on HPV Vaccination.
Study: NCT01710046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (CP-6890,550) Tofacitinib
Description: 2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
Study: NCT03266055

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 50 g of blueberry powder, taken daily for 8 weeks
Description: Subjects will consume blueberry powder during 8 weeks to test the possible effects of blueberries on gut microbiota composition and on metabolic syndrome parameters.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 50g of placebo blueberry powder, taken daily for 8 weeks
Description: Subjects will consume blueberry placebo powder to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and the active treatment (blueberry powder).
Study: NCT04678063

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exposure to Placebo
Description: Patients are exposed to placebo in the EEC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to Placebo
Description: Patients are exposed to placebo in the EEC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to dose A and dose B of cat allergen
Description: Patients are exposed to dose A and B for successive exposures in the EEC

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exposure to a single dose of cat allergen
Description: Patients are exposed to a single dose of cat allergen in the EEC according to the dose selected to achieve the main objective (dose A or B)
Study: NCT02056145

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FNB
Description: FNB - Chirocaine 0.25%, 20 cc
Study: NCT03433703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib capsules will be administered orally, once daily in continuous 28-day cycles.~Body weight (BW) ≥60 kilograms (kg) - Lenvatinib 12 mg (taken as three 4-mg capsules); BW \<60 kg - Lenvatinib 8 mg (taken as two 4-mg capsules)
Study: NCT01659034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thienopyridine for 3 months
Study: NCT03690089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine Sulfate
Description: Atropine sulfate 0.01% eye drops which consist of 10mls of a clear colourless solution of atropine sulfate 0.01% w/v and benzalkonium chloride 0.01% w/v in sterile water.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo eye drops which consist of 10mls of a clear colourless solution of benzalkonium chloride 0.01% w/v in sterile water.
Study: NCT04459676

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC) + ANG-3777
Description: Standard of Care (SOC) + ANG-3777

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard Of Care (SOC) + Placebo
Description: Standard Of Care + Placebo
Study: NCT01872000

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery
Study: NCT04419987

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: draw blood
Description: search for new genetic variations (when the diagnostic exploration will have been non informative) by sequencing exons.
Study: NCT01013337

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture therapy

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham intervention
Description: Placebo acupuncture
Study: NCT02163863

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Femoropopliteal stenting

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Femoropopliteal stenting
Study: NCT02985138

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TLIF and unilateral pedicle screw fixation
Description: TLIF combined with posterior unilateral pedicle screw fixation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TLIF and bilateral pedicle screw fixation
Description: TLIF combined with posterior bilateral pedicle screw fixation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pedicle screw and cage
Description: Pedicle screw and cage

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pedicle screw and cage
Description: Pedicle screw and cage
Study: NCT04053426

Intervention type: OTHER
Intervention: Implementation of agitation care algorithm
Description: Following the agitation care algorithm care professional adapt their behavior regarding agitation
Study: NCT02455726

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium oxide
Description: Oral magnesium oxide 300 mg twice a day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fructose
Description: Oral fructose 10 g twice a day
Study: NCT01710046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 matching oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (CP-690,550) Tofacitinib
Description: 2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 weeks
Study: NCT02455726

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxycodone
Description: Oxycodone hydrochloride 5 mg at 8 am

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Oxycodone hydrochloride 5 mg at 8 am

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin 25 mg at 8 pm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 25 mg at 8 pm
Study: NCT01710046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 matching oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
Study: NCT00975325

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yohimbine
Description: yohimbine 5 mg, one tablet, single dose only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yohimbine
Description: yohimbine 5 mg, one tablet, single dose only
Study: NCT00952042

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heavy slow resistance training
Description: Heel-raises. 12-6RM. each contraction performed slowly. three times weekly for 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric resistance training
Description: Eccentric heel-raises. 3 x 15 reps performed twice daily for 12 wks.
Study: NCT01975051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitefosine
Description: Tablet Miltefosine 100 mg in two devided doses for 12 weeks
Study: NCT00467857

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: InteguSeal* skin sealant and standard surgical preparation
Description: Surgical skin preparation prior to incision using InteguSeal\* skin sealant following standard surgical preparation with povidone iodine or 0.7% available iodine in isopropyl alcohol 74% w/w.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard preoperative skin preparation
Description: Surgical skin preparation prior to incision using standard surgical preparation with povidone iodine or 0.7% available iodine in isopropyl alcohol 74% w/w.
Study: NCT04924959

Intervention type: OTHER
Intervention: Logistic Regression Analysis
Description: Using logistic regression analysis to analyze the independent risk factors of PICC catheter displacement
Study: NCT01828879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus ointment, 0.1 percent will be applied twice daily, in adult population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
Study: NCT00177996

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline hydrochloride
Description: The study was a double-blind study in which subjects diagnosed with major depression complicated by lifetime panic spectrum symptomatology were randomized to either high (but still within the standards of normal clinical practice) or low dose titration schedules of sertraline. The doses and titration schedules used in this study are consistent with recommended FDA guidelines.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline hydrochloride
Description: The study was a double-blind study in which subjects diagnosed with major depression complicated by lifetime panic spectrum symptomatology were randomized to either high (but still within the standards of normal clinical practice) or low dose titration schedules of sertraline. The doses and titration schedules used in this study are consistent with recommended FDA guidelines.
Study: NCT00237627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS-341
Description: PS-341 will be administered as an intravenous push into a side arm of either a peripheral or central intravenous line infusing normal saline at 100 ml/hr. Patients will be treated twice weekly for two weeks, followed by a one week rest period, such that the typical days of treatment will be days 1, 4, 8, 11 of each three-week cycle. The initial dose level for PS-341 will be 0.9 mg/m2/dose intravenously, while subsequent dose levels will be determined according to a modified Fibonacci schema
Study: NCT02058472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G3041

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G3041
Study: NCT01355328

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser and radiofrequency
Description: different laser and radiofrequency with different fluences
Study: NCT03541239

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single Cuff Tourniquet 8000
Description: If randomized to ischemic conditioning the cuff will be inflated as stated before. If randomized to non-ischemic conditioning the cuff will not be inflated.
Study: NCT02058472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEVIKAR®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SEVIKAR®
Study: NCT04050072

Intervention type: OTHER
Intervention: Childhood Cancer Survivors (CCSS)
Description: To use the PRO-CTCAE-SCC (beta version) to identify symptomatic adverse event (AEs) that are prevalent and clinically meaningful in adult survivors of childhood cancer vs. non-cancer controls, and to create symptomatic AE items that are not included in the current PRO-CTCAE for adult survivors of childhood cancer.

Intervention type: OTHER
Intervention: SJLIFE
Description: To use the current PRO-CTCAE to conduct a symptom content creation process for the PRO-CTCAE-SCC by identifying clinically meaningful symptomatic AEs for adult survivors of childhood cancer, to create symptomatic AE items not included in the current PRO-CTCAE, and to perform comprehensive medical evaluation, physical performance evaluation, and neurocognitive evaluation to clinically validate the PRO-CTCAE-SCC.

Intervention type: OTHER
Intervention: Community non-cancer control
Description: To use the PRO-CTCAE-SCC (beta version) to identify symptomatic adverse event (AEs) that are prevalent and clinically meaningful in non-cancer controls vs. adult survivors of childhood cancer, and to create symptomatic AE items that are not included in the current PRO-CTCAE for adult survivors of childhood cancer.
Study: NCT00003927

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study: NCT03541239

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single Cuff Tourniquet 8000
Description: If randomized to ischemic conditioning the cuff will be inflated as stated before. If randomized to non-ischemic conditioning the cuff will not be inflated.
Study: NCT00237627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxil
Description: Doxil will be administered at a dose of 30 mg/m2 as a 1 hour infusion through either a peripheral or central intravenous line every 3 weeks (on day 4 of each 21 day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxil
Description: Doxil will be administered at a dose of 30 mg/m2 as a 1 hour infusion through either a peripheral or central intravenous line every 3 weeks (on day 4 of each 21 day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: Velcade will be adminstered intravenously at 1.3 mg/m2 days 1, 4, 8, 11 every 3 weeks
Study: NCT01459757

Intervention type: OTHER
Intervention: non-interventional
Description: Non-interventional; Mutational status data analyzed previously but not collected in the A6181036 study, will be correlated wth A6181036 clinical outcomes data collected during the A6181036 study.
Study: NCT02301741

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Game
Description: We will assess the influence of participation in a computer game of virtual dodge ball that requires whole-body reaching movements to manipulate an on-screen avatar. We will gradually reduce the gain of lumbar spine motion of the participant's on-screen avatar across the three game sessions such that participants will need to produce progressively larger excursions of the lumbar spine to manipulate their avatar's spinal motion. Specifically, in game session 1, the spine motion of the avatar is equal to that of the participant (gain=1); in session 2 spine motion of the avatar is 5% less than the participant (gain=0.95); in session 3 spine motion of the avatar is 10% less than the participant (gain=0.90).
Study: NCT01600339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CABAZITAXEL
Description: The patients are planned to receive cabazitaxel at a starting dose of 25 mg/m(2) intravenously over 1 h, following premedication as accepted with cabazitaxel. Treatment cycles are every 3 weeks. All patients will receive primary GCSF support.